Notice to convene Annual General Meeting

Orphazyme A/S
Company announcement

No. 04/2018                                                                                 

Copenhagen, Denmark, March 19, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the Orphazyme A/S Annual General Meeting will be held on:

Thursday, April 12, 2018 at 5:00 PM (CET)

at Gorrissen Federspiel Advokatpartnerselskab, Axeltorv 2, DK-1609 Copenhagen V.

The notice to convene the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached.

Additional information about the Annual General Meeting is available at Orphazyme A/S’ website, .


For additional information, please


Orphazyme A/S

Anders Vadsholt, CFO                         +45 28 98 90 55

About Orphazyme A/S
Orphazyme is a Danish biopharmaceutical company focused on the development of treatments for patients living with life-threatening or debilitating rare diseases. Our research is concentrated on the cell-protective properties of the body’s own rescue system for diseases caused by misfolded proteins or lysosomal dysfunction. The company’s lead candidate, arimoclomol, is in development for four severe orphan diseases; two muscle-wasting diseases, sporadic Inclusion Body Myositis (sIBM) and Amyotrophic Lateral Sclerosis (ALS), and two lysosomal storage diseases, Niemann-Pick disease Type C (NPC) and Gaucher disease. We are listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit .


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.